Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHENIX: Pyrotinib plus Capecitabine in HER2+ Metastatic Breast Cancer
NCT02973737Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Jul 2016
- Primary completion
- Jun 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Pyrotinib + Capecitabine with Placebo + Capecitabine (2 arms). Primary endpoint: Progression Free Survival at 10 months. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02973737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973737.